Trial Profile
Phase II study of IMO-2125 in combination with pembrolizumab in patients with non-small-cell-lung-cancer.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tilsotolimod (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
- 02 Aug 2018 According to the Idera Pharmaceuticals media release, The principal investigator is Arafat Tfayli, MD, Professor of Clinical Medicine, Director of Hematology/Oncology Fellowship Program at the American University of Beirut Medical Center (AUBMC), Lebanon.
- 23 Apr 2018 New trial record